Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M. Buse JB, et al. Among authors: schmidt we. J Clin Endocrinol Metab. 2011 Jun;96(6):1695-702. doi: 10.1210/jc.2010-2822. Epub 2011 Mar 30. J Clin Endocrinol Metab. 2011. PMID: 21450987 Clinical Trial.
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; Liraglutide Effect Action in Diabetes-6 Study Group. Buse JB, et al. Among authors: schmidt we. Diabetes Care. 2010 Jun;33(6):1300-3. doi: 10.2337/dc09-2260. Epub 2010 Mar 23. Diabetes Care. 2010. PMID: 20332351 Free PMC article. Clinical Trial.
[New concepts in the treatment of type 2 diabetes].
Meier JJ, Schmidt WE, Klein HH. Meier JJ, et al. Among authors: schmidt we. Internist (Berl). 2007 Jul;48(7):698, 700-7. doi: 10.1007/s00108-007-1876-z. Internist (Berl). 2007. PMID: 17541529 Review. German.
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ. Meier JJ, et al. Among authors: schmidt we. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. doi: 10.1152/ajpendo.00576.2005. Epub 2006 Jan 10. Am J Physiol Endocrinol Metab. 2006. PMID: 16403774 Free article.
321 results